Zotepine in the treatment of acute hospitalized schizophrenic episodes

International Clinical Psychopharmacology

Volumn 16, Issue 3, 2001, Pages 163-168

  Kasper, Siegfried ^a,h   Quiner, S ^a   Barnas, C ^a   Fabisch, H ^b   Haushofer, M ^c   Sackel, C ^d   Konig P ^e   Lingg, A ^e   Platz, T ^f   Rittmannsberger, H ^g   Stuppack C ^d   Willeit, M ^a   Zapotoczky, H G ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c DANUBE HOSPITAL   (Austria)

^d I Psychiatrische Abteilung   (Austria)

^e Abteilung für Psychiatrie und Neurologie   (Austria)

^f GENERAL HOSPITAL KLAGENFURT   (Austria)

^g KEPLER UNIVERSITY HOSPITAL   (Austria)

^h UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antipsychotics; Atypical antipsychotics; Post marketing surveillance study; Schizophrenia; Zotepine

Indexed keywords

NEUROLEPTIC AGENT; ZOTEPINE;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0035034704     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200105000-00005     Document Type: Article

References (21)

1. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: A retrospective analysis using the Saskatchewan Health linkable databases
2. Symptoms, signs, and diagnosis of schizophrenia
3. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol
4. 123I-IBZM SPECT imaging of dopamine-2 receptors in psychotic patients treated with zotepine
5. A rating scale for drug-induced akathisia
6. Neurocircuitries and neurotransmitter interactions in schizophrenia
7. Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain
8. The two-syndrome concept: Origins and status
9. Efficacy and tolerance of zotepine in a double-blind comparison with perazine in schizophrenics
10. Structure and course of positive and negative symptoms in schizophrenia
11. Zotepine vs haloperidol in paranoid schizophrenia: A double-blind trial
12. The positive and negative syndrome scale (PANSS) for schizophrenia
13. Double-blind comparison of 3 × 75 mg zotepine and 3 × 4 mg haloperidol in acute schizophrenics
14. Leitlinien zur durchführung von anwendungsbeobachtungen (AWB) in der psychopharmakotherapie
15. Neuroleptic treatment of negative symptoms in schizophrenic patients: Efficacy problems and methodological difficulties
16. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: A parallel-group double-blind trial
17. One-month prevalence of mental disorders in the United States. Based on five epidemiologic catchment area sites
18. A rating scale for extrapyramidal side effects
19. The diagnosis and understanding of schizophrenia, part III: Speculations on the processes that underlie schizophrenic symptoms and signs
20. Zotepine versus perazine in paranoid schizophrenia: A double-blind controlled trial of antipsychotic efficacy